Harvey Stevenson

Mr. Harvey Stevenson

Imperial College School of Medicine
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
HSHarvey Stevenson
Harvey Stevenson
SBSamuel Bartram
Samuel Bartram
MCMikaela Maria Charalambides
Mikaela Maria Charalambides
SMSruthi Murthy
Sruthi Murthy
TPTheo Petitt
Theo Petitt
AAAli Abbara
Ali Abbara
Feedback from oestradiol (E2) plays a critical role in the regulation of major events in the physiological menstrual cycle including the release of gonadotrophins to stimulate follicular growth, and the mid-cycle luteinising hormone (LH) surge that leads to ovulation. E2 predominantly exerts its action via oestrogen receptor-alpha (ERα), however, as gonadotrophin releasing hormone (GnRH) neurons lack ERα, E2-feedback is posited to be indirectly mediated via upstream neurons. Kisspeptin (KP) is a neuropeptide expressed in hypothalamic KP-neurons that control GnRH secretion and plays a key role in the central mechanism regulating the hypothalamic-pituitary-gonadal (HPG) axis. In the rodent arcuate (ARC) nucleus, KP is co-expressed with Neurokinin B and Dynorphin; and thus, these neurons are termed ‘Kisspeptin-Neurokinin B-Dynorphin’ (KNDy) neurons. ARC KP-neurons function as the ‘GnRH pulse generator’ to regulate GnRH pulsatility, as well as mediating negative feedback from E2. A second KP neuronal population is present in the rostral periventricular area of the third ventricle (RP3V), which includes anteroventral periventricular (AVPV) nucleus and preoptic area neurons. These RP3V KP-neurons mediate positive feedback to induce the mid-cycle luteinising hormone (LH) surge and subsequent ovulation. Here, we describe the role of KP-neurons in these two regions in mediating this differential feedback from oestrogens. We conclude by considering reproductive diseases for which exploitation of these mechanisms could yield future therapies.

29 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Waseem JerjesWaseem Jerjes
Waseem Jerjes
HSHarvey Stevenson
Harvey Stevenson
DRDaniele Ramsay
Daniele Ramsay
ZHZaid Hamdoon
Zaid Hamdoon
Introduction: Optical Coherence Tomography (OCT) has emerged as an important imaging modality in non-invasive diagnosis for oral cancer and can provide real-time visualisation of tissue morphology with the required high resolution. This systematic review aims to assess the diagnostic accuracy of OCT in the detection of oral cancers, and to explore the potential integration of OCT with artificial intelligence (AI) and other imaging techniques to enhance diagnostic precision and clinical outcomes in oral healthcare. Methods: A systematic literature search was conducted across PubMed, Embase, Scopus, Google Scholar, Cochrane Central Register, and Web of Science from inception until August 2024. Studies were included if they employed OCT for oral cancer detection, reported diagnostic outcomes, such as sensitivity and specificity, and were conducted on human subjects. Data extraction and quality assessment were performed independently by two reviewers. The synthesis highlights advancements in OCT technology, including AI-enhanced interpretations. Results: A total of 9 studies met the inclusion criteria, encompassing a total of 860 events (cancer detections). The studies spanned from 2008 to 2022 and utilised various OCT techniques, including clinician-based, algorithm-based, and AI-driven interpretations. The findings indicate OCT’s high diagnostic accuracy, with sensitivity ranging from 75% to 100% and specificity from 71% to 100%. AI-augmented OCT interpretations demonstrated the highest accuracy, emphasising OCT’s potential in early cancer detection and precision in guiding surgical interventions. Conclusions: OCT could play a very prominent role as a new diagnostic tool for oral cancer, with very high sensitivity and specificity. Future research pointed towards integrating OCT with other imaging methods and AI systems in providing better accuracy of diagnoses, plus more clinical usability. Further development and validation with large-scale multicentre trials is imperative for the realisation of this potential in changing the way we practice oral healthcare.

26 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DRDaniele Ramsay
Daniele Ramsay
HSHarvey Stevenson
Harvey Stevenson
Waseem JerjesWaseem Jerjes
Waseem Jerjes
Head and neck cancers are largely squamous cell carcinomas derived from the epithelial lining of the structures in the region, and are often classified anatomically into oral, oropharyngeal, nasopharyngeal and laryngeal carcinomas. The region’s component structures serve complex and intricate functions, such as speaking, swallowing and breathing, which are often compromised by these neoplasms. Such lesions may also cause disfigurement, leading to distressing social and psychological issues. Conventional treatments of these neoplasms usually involve surgical intervention with or without chemoradiotherapy. These have shown to be efficacious; however, they can also cause damage to healthy as well as diseased tissue, exacerbating the aforementioned problems. Access to a given region to deliver the treatments is also often a problem, due to the complex anatomical structures involved. The use of photodynamic therapy in the head and neck region has been established for about two decades. In this review, we looked at the basic mechanisms of this intervention, examined its use in common head and neck malignancies and vascular anomalies, and reported on the most recent clinical studies. We further included a clinical guide which can help replicate the use of this technology by any unit. Based on this review, photodynamic therapy has been shown to be efficacious in the treatment of head and neck malignancies and vascular tumours. This therapy can be targeted to the diseased tissue and causes no damage to underlying structures. Recent studies have shown this therapy to be as effective as conventional therapies, without causing major adverse effects.

13 February 2024 in Foot and Ankle Surgery
Verified
Journal Article
Closed access
Waseem JerjesWaseem Jerjes
Waseem Jerjes
DRDaniele Ramsay
Daniele Ramsay
HSHarvey Stevenson
Harvey Stevenson
AYAamr Yousif
Aamr Yousif

7 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Waseem JerjesWaseem Jerjes
Waseem Jerjes
DRDaniele Ramsay
Daniele Ramsay
HSHarvey Stevenson
Harvey Stevenson
KLKarima Lalji
Karima Lalji
Background: Mental health (MH) polypharmacy, defined as prescribing multiple mental health medications for the same condition, presents significant challenges in clinical practice. With varying prevalence rates and an increasing trend, particularly in the UK, this deprescribing prospective quality improvement project aimed to address the complexities and risks associated with MH polypharmacy. Patients and Methods: A large primary care centre in London was selected for this project. Electronic records of 667 patients (non-coded in mental health lists) were analysed as a result of the absence of a Systematised Nomenclature of Medicine Clinical Terms (SNOMED CT) for mental health. Seventy-two non-coded patients exhibiting “same-class” as well as “adjunctive” and “augmentation” polypharmacy were identified. Their demographic and health data, including MH diagnoses, physical status, and lifestyle habits, were evaluated. This deprescribing prospective project included 68 patients and employed a model inspired by the Plan–Do–Study–Act (PDSA) cycle, focusing on reducing psychotropic, adjunctive, and augmentative medications while monitoring mental health control through face-to-face consultations using the Patient Health Questionnaire-9 (PHQ-9) and Generalised Anxiety Disorder Assessment-7 (GAD-7) scores, alongside physical health parameters. Results: The project revealed a significant decrease in the average number of psychotropic and adjunct medications from initial consultations to the end of the 18-month period. Additionally, a marked reduction in reported side effects and drug interactions was observed. Improvements in mental health control, as evidenced by PHQ-9 and GAD-7 scores, were noted. Physical health parameters, including BMI, blood pressure, heart rate, HbA1c, and cholesterol levels, also showed significant improvements. Educational initiatives for patients and clinicians were successfully implemented, contributing to these positive outcomes. Discussion: The project faced challenges like balancing medication reduction with mental health stability, patient apprehension, and the absence of standardised protocols. However, the successful reduction in medication numbers and the improvement in health outcomes highlight the effectiveness of the model. This project underscores the necessity of a tailored approach to MH polypharmacy, emphasising continuous education, clinical titration, and adherence to guidelines. Future research is needed to develop clear guidelines for medication combination in mental health care and to understand the long-term effects of polypharmacy in mental health populations. Conclusions: This project demonstrates the potential for significant improvements in the management of MH polypharmacy. By carefully managing medication reductions and employing a comprehensive care approach, including patient education and clinician training, the project achieved improvements in both mental and physical health outcomes. These findings suggest a promising direction for future practices in MH polypharmacy management.

10 March 2022 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
Waseem JerjesWaseem Jerjes
Waseem Jerjes
HSHarvey Stevenson
Harvey Stevenson
DRDaniele Ramsay
Daniele Ramsay
ZHZaid Hamdoon
Zaid Hamdoon
CHColin Hopper
Colin Hopper